Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial https://t.co/h6WhypjKtH
RT @DanielJDrucker: Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to op…
RT @CircAHA: #ICYMI: Efpeglenatide Dose and CV Outcomes in Diabetes @PHRIresearch #AHAJournals
RT @CircAHA: #ICYMI: Efpeglenatide Dose and CV Outcomes in Diabetes @PHRIresearch #AHAJournals
RT @CircAHA: #ICYMI: Efpeglenatide Dose and CV Outcomes in Diabetes @PHRIresearch #AHAJournals
RT @CircAHA: #ICYMI: Efpeglenatide Dose and CV Outcomes in Diabetes @PHRIresearch #AHAJournals
#ICYMI: Efpeglenatide Dose and CV Outcomes in Diabetes @PHRIresearch #AHAJournals
Wow! Significant difference in not just MACE but composite kidney outcomes with up titration of dose? Another med class to maximize the dose, to max the gains, I guess? Cost and formulary availability are still a barrier to even initiate. #CardioTwitter #
RT @CircAHA: #OriginalResearch Insights from the AMPLITUDE-O Trial: Titration of Efpeglenatide and other GLP-1 agonists may maximize CV ben…
RT @CircAHA: #OriginalResearch Insights from the AMPLITUDE-O Trial: Titration of Efpeglenatide and other GLP-1 agonists may maximize CV ben…
RT @CircAHA: #OriginalResearch Insights from the AMPLITUDE-O Trial: Titration of Efpeglenatide and other GLP-1 agonists may maximize CV ben…
RT @CircAHA: #OriginalResearch Insights from the AMPLITUDE-O Trial: Titration of Efpeglenatide and other GLP-1 agonists may maximize CV ben…
RT @CircAHA: #OriginalResearch Insights from the AMPLITUDE-O Trial: Titration of Efpeglenatide and other GLP-1 agonists may maximize CV ben…
RT @CircAHA: #OriginalResearch Insights from the AMPLITUDE-O Trial: Titration of Efpeglenatide and other GLP-1 agonists may maximize CV ben…
RT @CircAHA: #OriginalResearch Insights from the AMPLITUDE-O Trial: Titration of Efpeglenatide and other GLP-1 agonists may maximize CV ben…
#OriginalResearch Insights from the AMPLITUDE-O Trial: Titration of Efpeglenatide and other GLP-1 agonists may maximize CV benefits #AHAJournals @PHRIresearch https://t.co/I5vPWQyTPT https://t.co/6hrQ4YhTRY
RT @DanielJDrucker: Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to op…
RT @DanielJDrucker: Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to op…
RT @DanielJDrucker: Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to op…
RT @DanielJDrucker: Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to op…
RT @mbotana: Titular los GLP1-RA a dosis altas puede maximizar sus beneficios cardiovasculares y renales - Exploring the Relationship Betwe…
RT @DanielJDrucker: Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to op…
RT @DanielJDrucker: Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to op…
This isn’t getting the attention it deserves! Suggests that sole focus on dosing to glycemic control is likely outdated, and we likely could be doing better to maximize effect and reduce cardiorenal risk without additional medication burden. Bodes well for
RT @mbotana: Titular los GLP1-RA a dosis altas puede maximizar sus beneficios cardiovasculares y renales - Exploring the Relationship Betwe…
RT @mbotana: Titular los GLP1-RA a dosis altas puede maximizar sus beneficios cardiovasculares y renales - Exploring the Relationship Betwe…
Article by Professor Naveed Sattar #published in @CircAHA "Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial" 🧾More info➡️https://t.co/tPdZDe56eJ #research #science ht
RT @mbotana: Titular los GLP1-RA a dosis altas puede maximizar sus beneficios cardiovasculares y renales - Exploring the Relationship Betwe…
RT @mbotana: Titular los GLP1-RA a dosis altas puede maximizar sus beneficios cardiovasculares y renales - Exploring the Relationship Betwe…
Perhaps the best paper to date to suggest higher doses of GLP-1RA may reduce outcomes risks more, from Prof Naveed Sattar @UofGSCMH and international colleagues https://t.co/Cmy0PYoA6K
Titular los GLP1-RA a dosis altas puede maximizar sus beneficios cardiovasculares y renales - Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial https://t.co/eLxKQfzlay
RT @Office_j: 【2型DMに対するGLP-1-RA心腎保護作用に用量依存性?AMPLITUDE-O/ Circ】 CV高リスク2型DM 4076例ランダム化:GLP-1-RA高用量群の対プラセボMACE HRは0,65 [95%CI 0.50-0.86]も、低用量…
RT @Office_j: 【2型DMに対するGLP-1-RA心腎保護作用に用量依存性?AMPLITUDE-O/ Circ】 CV高リスク2型DM 4076例ランダム化:GLP-1-RA高用量群の対プラセボMACE HRは0,65 [95%CI 0.50-0.86]も、低用量…
【2型DMに対するGLP-1-RA心腎保護作用に用量依存性?AMPLITUDE-O/ Circ】 CV高リスク2型DM 4076例ランダム化:GLP-1-RA高用量群の対プラセボMACE HRは0,65 [95%CI 0.50-0.86]も、低用量では0.82 [0.63-1.06]。用量依存性p<0.05。腎イベントも同様。 https://t.co/1EAvztY9Nc https://t.co/mNPMEb3gXI
RT @DanielJDrucker: Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to op…
My view: epidemiology via large community studies indicating veggies & fruit, intact grains lower risk. pathophysiology was unclear. new meds helping to unfold mechanism of action. incretin responses to food. microbiome can be a confound.
RT @DanielJDrucker: Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to op…
RT @DanielJDrucker: Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to op…
RT @DanielJDrucker: Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to op…
RT @DanielJDrucker: Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to op…
RT @DanielJDrucker: Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to op…
Lessons from AMPLITUDE-O. Titrating efpeglenatide and potentially other glucagon-like peptide-1 receptor agonists to optimize target engagement may maximize their cardiovascular and renal benefits @CircAHA #heartdisease #CVD https://t.co/DVZTIuB7zP https:/